Home | Welcome to Contract Pharma   
Last Updated Tuesday, July 29 2014
Print RSS Feed

Financial Report: Dendreon



By Kristin Brooks



Published March 3, 2014
Related Searches: CMO
Dendreon

4Q Revenues: $74.8 million (-12%)

4Q Loss: $88.7 million (loss of $38.7 million 4Q12)

FY Revenues: $283.7 million (-13%)

FY Loss: $296.8 million (loss of $393.6 million FY12)

Comments: The company added 31 new accounts for PROVENGE in the quarter and implemented a new commercial model. The company will make PROVENGE available in Europe through Centers of Excellence using CMO PharmaCell, beginning with Germany and the UK. Royalty and other revenues were down to $7 million in the quarter, from $38 million in 4Q12.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On